Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kubota Vision Inc.
This 510(k)-enabling study is designed to assess the performance and usability of the RHMS Visual Acuity Module in normal patients and patients with neovascular AMD.
Age
50–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Cohort 1 - Normal subjects
1. Age ≥ 50 years
2. Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye
3. Able to perform self-testing with the Visual Acuity Module of the RHMS after training
4. Able and willing to give informed consent
Cohort 2 - Subjects with neovascular AMD
1. Age ≥ 50 years
2. History of neovascular age-related macular degeneration, in the study eye
3. Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye
You may not be if
Cohort 1 - Normal subjects
1. History of ophthalmic disease resulting in decrease in visual acuity per the Investigator, in the study eye
2. Use of any investigational drug in the past 30 days, or investigational, interventional device in the past 60 days
Cohort 2 - Subjects with neovascular AMD
1. History of geographic atrophy or macular atrophy within the central 3 mm of the macula, in the study eye
2. History of macular hole in the study eye
3. Use of any investigational drug in the past 30 days, or investigational, interventional device in the past 60 days
Clareo Health | Study Evaluating Retinal Health Monitoring System Visual Acuity Module.
